• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Kwok Kin Wong, MD, PhD


  • Kawabata S, Mercado-Matos JR, Hollander MC, Donahue D, Wilson W, Regales L, Butaney M, Pao W, Wong KK, Jänne PA, Dennis PA.Rapamycin Prevents the Development and Progression of Mutant Epidermal Growth Factor Receptor Lung Tumors with the Acquired Resistance Mutation T790M.Cell Rep. 2014 Jun 11.
  • Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, ten Hacken E, Bertilaccio MT, Antonini E, Neri A, Ponzoni M, Marcatti M, Richardson PG, Carrasco R, Kimmelman AC, Wong KK, Caligaris-Cappio F, Blandino G, Kuehl WM, Anderson KC, Tonon G.Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.Nat Med. 2014 Jun;20(6):599-606.
  • Hata AN, Yeo A, Faber AC, Lifshits E, Chen Z, Cheng KA, Walton Z, Sarosiek KA, Letai A, Heist RS, Mino-Kenudson M, Wong KK, Engelman JA.Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.Cancer Res. 2014 Jun 1(11):3146-56.
  • Xu C, Fillmore CM, Koyama S, Wu H, Zhao Y, Chen Z, Herter-Sprie GS, Akbay EA, Tchaicha JH, Altabef A, Reibel JB, Walton Z, Ji H, Watanabe H, Jänne PA, Castrillon DH, Rustgi AK, Bass AJ, Freeman GJ, Padera RF, Dranoff G, Hammerman PS, Kim CF, Wong KK.Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression.Cancer Cell. 2014 May 12;25(5):590-604.
  • Muvaffak A, Pan Q, Yan H, Fernandez R, Lim J, Dolinski B, Nguyen TT, Strack P, Wu S, Chung R, Zhang W, Hulton C, Ripley S, Hirsch H, Nagashima K, Wong KK, Janne PA, Seidel-Dugan C, Zawel L, Kirschmeier PT, Middleton RE, Morris EJ, Wang Y.Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3.Mol Cancer Res. 2014 Apr 21.
  • Zhu Z, Aref AR, Cohoon TJ, Barbie TU, Imamura Y, Yang S, Moody SE, Shen RR, Schinzel AC, Thai TC, Reibel JB, Tamayo P, Godfrey JT, Qian ZR, Page AN, Maciag K, Chan EM, Silkworth W, Labowsky MT, Rozhansky L, Mesirov JP, Gillanders WE, Ogino S, Hacohen N, Gaudet S, Eck MJ, Engelman JA, Corcoran RB, Wong KK, Hahn WC, Barbie DA.Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.Cancer Discovery. 2014 Apr;4(4):452-65.
  • Watanabe H, Ma Q, Peng S, Adelmant G, Swain D, Song W, Fox C, Francis JM, Pedamallu CS, Deluca DS, Brooks AN, Wang S, Que J, Rustgi AK, Wong KK, Ligon KL, Liu XS, Marto JA, Meyerson M, Bass AJ.SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas.J Clin Invest. 2014 Apr 1;124(4):1636-45.
  • Lau AN, Curtis SJ, Fillmore CM, Rowbotham SP, Mohseni M, Wagner DE, Beede AM, Montoro DT, Sinkevicius KW, Walton ZE, Barrios J, Weiss DJ, Camargo FD, Wong KK, Kim CF.Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis.EMBO J. 2014 Mar 3;33(5):468-81.
  • Chen Z, Akbay E, Mikse O, Tupper T, Cheng K, Wang Y, Tan X, Altabef A, Woo SA, Chen L, Reibel JB, Janne PA, Sharpless NE, Engelman JA, Shapiro GI, Kung AL, Wong KK.Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance.Clin Cancer Res. 2014 Mar 1;20(5):1204-11.
  • Akbay EA, Moslehi J, Christensen CL, Saha S, Tchaicha JH, Ramkissoon SH, Stewart KM, Carretero J, Kikuchi E, Zhang H, Cohoon TJ, Murray S, Liu W, Uno K, Fisch S, Jones K, Gurumurthy S, Gliser C, Choe S, Keenan M, Son J, Stanley I, Losman JA, Padera R, Bronson RT, Asara JM, Abdel-Wahab O, Amrein PC, Fathi AT, Danial NN, Kimmelman AC, Kung AL, Ligon KL, Yen KE, Kaelin WG, Bardeesy N, Wong KK.D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.Genes Dev. 2014 Mar 1;28(5):479-90.
  • DiRocco DP, Bisi J, Roberts P, Strum J, Wong KK, Sharpless N, Humphreys BD.CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury.Am J Physiol Renal Physiol. 2014 Feb 15;306(4):F379-88.
  • Han X, Li F, Fang Z, Gao Y, Li F, Fang R, Yao S, Sun Y, Li L, Zhang W, Ma H, Xiao Q, Ge G, Fang J, Wang H, Zhang L, Wong KK, Chen H, Hou Y, Ji H.Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma.Nat Commun. 2014;5:3261.
  • Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG.The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.Science. 2014 Jan 17;343(6168):305-9.
  • Fang R, Zheng C, Sun Y, Han X, Gao B, Li C, Liu H, Wong KK, Liu XY, Chen H, Ji H.Integrative genomic analysis reveals a high frequency of LKB1 genetic alteration in Chinese lung adenocarcinomas.J Thorac Oncol. 2014 Feb;9(2):254-8.
  • Mohseni M, Sun J, Lau A, Curtis S, Goldsmith J, Fox VL, Wei C, Frazier M, Samson O, Wong KK, Wong KK, Kim C, Camargo FD.A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway.Nat Cell Biol. 2014 Jan;16(1):108-17.
  • Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, Cohoon TJ, Janne PA, Meyerson M, Hayes DN, Shapiro GI, Shimamura T, Sholl LM, Rodig SJ, Freeman GJ, Hammerman PS, Dranoff G, Wong KK.Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.Cancer Discovery. 2013 Dec(12):1355-63.
  • Beauchamp EM, Woods BA, Dulak AM, Tan L, Xu C, Gray NS, Bass AJ, Wong KK, Meyerson M, Hammerman PS.Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.Mol Cancer Ther. 2013 Dec 2.
  • Tan X, Carretero J, Chen Z, Zhang J, Wang Y, Chen J, Li X, Ye H, Tang C, Cheng X, Hou N, Yang X, Wong KK.Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.PLoS ONE. 2013;8(11):e80885.
  • Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, Akbay E, Kimmelman AC, Kung AL, Bradner JE, Wong KK.Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.Clin Cancer Res. 2013 Nov 15;19(22):6183-92.
  • Cho J, Chen L, Sangji N, Okabe T, Yonesaka K, Francis JM, Flavin RJ, Johnson W, Kwon J, Yu S, Greulich H, Johnson BE, Eck MJ, Jänne PA, Wong KK, Meyerson M.Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.Cancer Res. 2013 Nov 15;73(22):6770-9.
  • Abazeed ME, Adams DJ, Hurov KE, Tamayo P, Creighton CJ, Sonkin D, Giacomelli AO, Du C, Fries DF, Wong KK, Mesirov JP, Loeffler JS, Schreiber SL, Hammerman PS, Meyerson M.Integrative radiogenomic profiling of squamous cell lung cancer.Cancer Res. 2013 Oct 15;73(20):6289-98.
  • Nakada Y, Stewart TG, Peña CG, Zhang S, Zhao N, Bardeesy N, Sharpless NE, Wong KK, Hayes DN, Castrillon DH.The LKB1 tumor suppressor as a biomarker in mouse and human tissues.PLoS ONE. 2013;8(9):e73449.
  • Liao RG, Jung J, Tchaicha J, Wilkerson MD, Sivachenko A, Beauchamp EM, Liu Q, Pugh TJ, Pedamallu CS, Hayes DN, Gray NS, Getz G, Wong KK, Haddad RI, Meyerson M, Hammerman PS.Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.Cancer Res. 2013 Aug 15;73(16):5195-205.
  • Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, Driggers EM, Zhang J, Bailey ST, Sharpless NE, Hayes DN, Patel NM, Janne PA, Bardeesy N, Engelman JA, Manning BD, Shaw RJ, Asara JM, Scully R, Kimmelman A, Byers LA, Gibbons DL, Wistuba II, Heymach JV, Kwiatkowski DJ, Kim WY, Kung AL, Gray NS, Root DE, Cantley LC, Wong KK.Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.Cancer Discovery. 2013 Aug;3(8):870-9.
  • Grugan KD, Vega ME, Wong GS, Diehl JA, Bass AJ, Wong KK, Nakagawa H, Rustgi AK.A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion.Cancer Biol Ther. 2013 Jun 18;14(9).
  • Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI.A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.Clin Cancer Res. 2013 Jun 1;19(11):3068-77.
  • Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, Osborne LD, Siegel MB, Duncan LM, O'Brien ET, Superfine R, Miller CR, Simon MC, Wong KK, Kim WY.HIF1α and HIF2α independently activate SRC to promote melanoma metastases.J Clin Invest. 2013 May 1;123(5):2078-93.
  • Fan YX, Wong L, Marino MP, Ou W, Shen Y, Wu WJ, Wong KK, Reiser J, Johnson GR.Acquired Substrate Preference for GAB1 Bestows Transforming Activity to ERBB2 Lung Cancer Mutants.J Biol Chem. 2013 Apr 23.
  • Xiao Z, Jiang Q, Willette-Brown J, Xi S, Zhu F, Burkett S, Back T, Song NY, Datla M, Sun Z, Goldszmid R, Lin F, Cohoon T, Pike K, Wu X, Schrump DS, Wong KK, Young HA, Trinchieri G, Wiltrout RH, Hu Y.The Pivotal Role of IKKα in the Development of Spontaneous Lung Squamous Cell Carcinomas.Cancer Cell. 2013 Apr 15;23(4):527-40.
  • Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, Wang Y, Tupper T, Altabef A, Kawamura H, Held KD, Chou DM, Elledge SJ, Janne PA, Wong KK, Sabatini DM, Gray NS.Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR.Cancer Res. 2013 Apr 15;73(8):2574-2586.
  • Sholl LM, Weremowicz S, Gray SW, Wong KK, Chirieac LR, Lindeman NI, Hornick JL.Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas.J Thorac Oncol. 2013 Mar;8(3):322-8.
  • Solimini NL, Liang AC, Xu C, Pavlova NN, Xu Q, Davoli T, Li MZ, Wong KK, Elledge SJ.STOP gene Phactr4 is a tumor suppressor.Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):E407-14.
  • Cortot AB, Repellin CE, Shimamura T, Capelletti M, Zejnullahu K, Ercan D, Christensen JG, Wong KK, Gray NS, Jänne PA.Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.Cancer Res. 2013 Jan 15;73(2):834-43.
  • Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, Song Y, Lifshits E, Hung KE, Shioda T, Dias-Santagata D, Singh A, Settleman J, Benes CH, Mino-Kenudson M, Wong KK, Engelman JA.Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.Cancer Cell. 2013 Jan 14;23(1):121-8.
  • Tzatsos A, Paskaleva P, Ferrari F, Deshpande V, Stoykova S, Contino G, Wong KK, Lan F, Trojer P, Park PJ, Bardeesy N.KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.J Clin Invest. 2013 Jan 16.
  • Weaver Z, Difilippantonio S, Carretero J, Martin PL, El Meskini R, Iacovelli AJ, Gumprecht M, Kulaga A, Guerin T, Schlomer J, Baran M, Kozlov S, McCann T, Mena S, Al-Shahrour F, Alexander D, Wong KK, Van Dyke T.Temporal Molecular and Biological Assessment of an Erlotinib-Resistant Lung Adenocarcinoma Model Reveals Markers of Tumor Progression and Treatment Response.Cancer Res. 2012 Nov 15;72(22):5921-5933.
  • Feng Y, Wang Y, Wang Z, Fang Z, Li F, Gao Y, Liu H, Xiao T, Li F, Zhou Y, Zhai Q, Liu X, Sun Y, Bardeesy N, Wong KK, Chen H, Xiong ZQ, Ji H.The CRTC1-NEDD9 signaling axis mediates lung cancer progression caused by LKB1 loss.Cancer Res. 2012 Oct 16.
  • Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, Goetz EM, Letai A, Garraway LA, Lazzara MJ, Rosen N, Gray NS, Wong KK, Jänne PA.Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.Cancer Discovery. 2012 Oct;2(10):934-47.
  • Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI.Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.Clin Cancer Res. 2012 Sep 15;18(18):4973-85.
  • Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka KE, Yun CH, Zhang X, Lee SH, Cho J, Ambrogio L, Liao R, Imielinski M, Banerji S, Berger AH, Lawrence MS, Zhang J, Pho NH, Walker SR, Winckler W, Getz G, Frank D, Hahn WC, Eck MJ, Mani DR, Jaffe JD, Carr SA, Wong KK, Meyerson M.Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14476-81.
  • Xu L, Kikuchi E, Xu C, Ebi H, Ercan D, Cheng KA, Padera R, Engelman JA, Jänne PA, Shapiro GI, Shimamura T, Wong KK.Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.Cancer Res. 2012 Jul 1;72(13):3302-11.
  • Liu W, Monahan KB, Pfefferle AD, Shimamura T, Sorrentino J, Chan KT, Roadcap DW, Ollila DW, Thomas NE, Castrillon DH, Miller CR, Perou CM, Wong KK, Bear JE, Sharpless NE.LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma.Cancer Cell. 2012 Jun 12;21(6):751-64.
  • Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D, Xu C, Wang Y, Aldelmant GO, Capelletti M, Lee HJ, Rodig SJ, Borgman CL, Park SI, Kim HR, Padera RF, Marto J, Gray N, Kung AL, Shapiro GI, Janne PA, Wong KK.Inhibition of ALK, PI3K/MEK and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene.Cancer Res. 2010 Dec 1;70(23):9827-36.
  • Gao Y, Xiao Q, Ma H, Li L, Liu J, Feng Y, Fang Z, Wu J, Han X, Zhang J, Sun Y, Wu G, Padera R, Chen H, Wong KK, Ge G, Ji H.LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling.Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18892-7.
  • Marcinkowska M, Wong KK, Kwiatkowski DJ, Kozlowski P.Design and generation of MLPA probe sets for combined copy number and small-mutation analysis of human genes: EGFR as an example.ScientificWorldJournal. 2010;10:2003-18.
  • Curtis SJ, Sinkevicius KW, Li D, Lau AN, Roach RR, Zamponi R, Woolfenden AE, Kirsch DG, Wong KK, Kim CF.Primary tumor genotype is an important determinant in identification of lung cancer propagating cells.Cell Stem Cell. 2010 Jul 2;7(1):127-33.
  • Johnson SM, Torrice CD, Bell JF, Monahan KB, Jiang Q, Wang Y, Ramsey MR, Jin J, Wong KK, Su L, Zhou D, Sharpless NE.Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition.J Clin Invest. 2010 Jul 1;120(7):2528-36.
  • Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, Ananthakrishnan R, Quinn S, Soria JC.Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.J Clin Oncol. 2010 Jun 20;28(18):3076-83.
  • Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, Borgman CL, Buttarazzi MS, Sanofsky BA, McNamara KL, Brandstetter KA, Walton ZE, Gu TL, Silva JC, Crosby K, Shapiro GI, Maira SM, Ji H, Castrillon DH, Kim CF, García-Echeverría C, Bardeesy N, Sharpless NE, Hayes ND, Kim WY, Engelman JA, Wong KK.Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.Cancer Cell. 2010 Jun 15;17(6):547-59.
  • Yang JY, Chang CJ, Xia W, Wang Y, Wong KK, Engelman JA, Du Y, Andreeff M, Hortobagyi GN, Hung MC.Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer.Cancer Res. 2010 Jun 1;70(11):4709-18.
  • Faber AC, Wong KK, Engelman JA.Differences underlying EGFR and HER2 oncogene addiction.Cell Cycle. 2010 Mar 1;9(5):851-2.
  • Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK, Brandstetter K, Wittner B, Ramaswamy S, Classon M, Settleman J.A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.Cell. 2010 Apr 2;141(1):69-80.
  • Wong KK, Jacks T, Dranoff G.NF-kappaB fans the flames of lung carcinogenesis.Cancer Prev Res (Phila Pa). 2010 Apr;3(4):403-5. Review.
  • Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, Burenkova O, Pace E, Walton Z, Nie L, Fulgham A, Song Y, Nielsen UB, Engelman JA, Wong KK.An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation.Cancer Res. 2010 Mar 15;70(6):2485-94.
  • Contreras CM, Akbay EA, Gallardo TD, Haynie JM, Sharma S, Tagao O, Bardeesy N, Takahashi M, Settleman J, Wong KK, Castrillon DH.Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy.Dis Model Mech.;3(3-4):181-93.
  • Wong KK, Engelman JA, Cantley LC.Targeting the PI3K signaling pathway in cancer.Curr Opin Genet Dev. 2010 Feb;20(1):87-90. Review.
  • Roccaro AM, Sacco A, Husu EN, Pitsillides C, Vesole S, Azab AK, Azab F, Melhem M, Ngo HT, Quang P, Maiso P, Runnels J, Liang MC, Wong KK, Lin C, Ghobrial IM.Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.Blood. 2010 Jan 21;115(3):559-69.
  • Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS, Jänne PA.Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.Nature. 2009 Dec 24;462(7276):1070-4.
  • Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT, Lifshits E, Chen Z, Maira SM, García-Echeverría C, Wong KK, Engelman JA.Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19503-8.
  • Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, Ramos AH, Woo MS, Weir BA, Getz G, Beroukhim R, O'Kelly M, Dutt A, Rozenblatt-Rosen O, Dziunycz P, Komisarof J, Chirieac LR, Lafargue CJ, Scheble V, Wilbertz T, Ma C, Rao S, Nakagawa H, Stairs DB, Lin L, Giordano TJ, Wagner P, Minna JD, Gazdar AF, Zhu CQ, Brose MS, Cecconello I, Jr UR, Marie SK, Dahl O, Shivdasani RA, Tsao MS, Rubin MA, Wong KK, Regev A, Hahn WC, Beer DG, Rustgi AK, Meyerson M.SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.Nat Genet. 2009 Nov;41(11):1238-42.
  • Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, Heynck S, Stückrath I, Weiss J, Fischer F, Michel K, Goel A, Regales L, Politi KA, Perera S, Getlik M, Heukamp LC, Ansén S, Zander T, Beroukhim R, Kashkar H, Shokat KM, Sellers WR, Rauh D, Orr C, Hoeflich KP, Friedman L, Wong KK, Pao W, Thomas RK.Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.Proc Natl Acad Sci U S A. 2009 Oct 27;106(43):18351-6.
  • Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, Ramos AH, Woo MS, Weir BA, Getz G, Beroukhim R, O'Kelly M, Dutt A, Rozenblatt-Rosen O, Dziunycz P, Komisarof J, Chirieac LR, Lafargue CJ, Scheble V, Wilbertz T, Ma C, Rao S, Nakagawa H, Stairs DB, Lin L, Giordano TJ, Wagner P, Minna JD, Gazdar AF, Zhu CQ, Brose MS, Cecconello I, Jr UR, Marie SK, Dahl O, Shivdasani RA, Tsao MS, Rubin MA, Wong KK, Regev A, Hahn WC, Beer DG, Rustgi AK, Meyerson M.SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.Nat Genet. 2009 Nov;41(11):1238-42.
  • Kim WY, Perera S, Zhou B, Carretero J, Yeh JJ, Heathcote SA, Jackson AL, Nikolinakos P, Ospina B, Naumov G, Brandstetter KA, Weigman VJ, Zaghlul S, Hayes DN, Padera RF, Heymach JV, Kung AL, Sharpless NE, Kaelin WG, Wong KK.HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice.J Clin Invest. 2009 Aug;119(8):2160-70.
  • Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T, Huang J, Saci A, Widlund HR, Fisher DE, Xiao Y, Rimm DL, Protopopov A, Wong KK, Chin L.GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer.Nature. 2009 Jun 25;459(7250):1085-90.
  • Sos ML,Michel K,Zander T,Weiss J,Frommolt P,Peifer M,Li D,Ullrich R,Koker M,Fischer F,Shimamura T,Rauh D,Mermel C,Fischer S,Stuckrath I,Heynck S,Beroukhim R,Lin W,Winckler W,Shah K,LaFramboise T,Moriarty WF,Hanna M,Tolosi L,Rahnenfuhrer J,Verhaak R,Chiang D,Getz G,Hellmich M,Wolf J,Girard L,Peyton M,Weir BA,Chen TH,Greulich H,Barretina J,Shapiro GI,Garraway LA,Gazdar AF,Minna JD,Meyerson M,Wong KK,Thomas RK.Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.J Clin Invest. 2009 Jun;119(6):1727-40.
  • Wingo SN,Gallardo TD,Akbay EA,Liang MC,Contreras CM,Boren T,Shimamura T,Miller DS,Sharpless NE,Bardeesy N,Kwiatkowski DJ,Schorge JO,Wong KK,Castrillon DH.Somatic LKB1 mutations promote cervical cancer progression.PLoS ONE. 2009;4(4):e5137.
  • Gandhi L,McNamara KL,Li D,Borgman CL,McDermott U,Brandstetter KA,Padera RF,Chirieac LR,Settleman JE,Wong KK.Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis.Cancer Prev Res (Phila Pa). 2009 Apr;2(4):330-7.
  • Wong KK,Fracasso PM,Bukowski RM,Lynch TJ,Munster PN,Shapiro GI,Janne PA,Eder JP,Naughton MJ,Ellis MJ,Jones SF,Mekhail T,Zacharchuk C,Vermette J,Abbas R,Quinn S,Powell C,Burris HA.A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.Clin Cancer Res. 2009 Apr 1;15(7):2552-8.
  • Schittenhelm MM,Kollmannsberger C,Oechsle K,Harlow A,Morich J,Honecker F,Kurek R,Storkel S,Kanz L,Corless CL,Wong KK,Bokemeyer C,Heinrich MC.Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer.Mol Cancer Ther. 2009 Mar;8(3):481-9.
  • Perera SA,Li D,Shimamura T,Raso MG,Ji H,Chen L,Borgman CL,Zaghlul S,Brandstetter KA,Kubo S,Takahashi M,Chirieac LR,Padera RF,Bronson RT,Shapiro GI,Greulich H,Meyerson M,Guertler U,Chesa PG,Solca F,Wistuba II,Wong KK.HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):474-9.
  • Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, Garca-Echeverra C, Weissleder R, Mahmood U, Cantley LC, Wong KK.Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.Nat Med. 2008 Dec;14(12):1351-6.
  • Girnun GD,Chen L,Silvaggi J,Drapkin R,Chirieac LR,Padera RF,Upadhyay R,Vafai SB,Weissleder R,Mahmood U,Naseri E,Buckley S,Li D,Force J,McNamara K,Demetri G,Spiegelman BM,Wong KK.Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.Clin Cancer Res. 2008 Oct 15;14(20):6478-86.
  • Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK.BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.Oncogene. 2008 Aug 7;27(34):4702-11.
  • Shimamura T,Li D,Ji H,Haringsma HJ,Liniker E,Borgman CL,Lowell AM,Minami Y,McNamara K,Perera SA,Zaghlul S,Thomas RK,Greulich H,Kobayashi S,Chirieac LR,Padera RF,Kubo S,Takahashi M,Tenen DG,Meyerson M,Wong KK,Shapiro GI.Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.Cancer Res. 2008 Jul 15;68(14):5827-38.
  • Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap BY, Meyerson M, Wong KK, Richards WG, Sugarbaker DJ, Johnson BE, Jänne PA.Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.Br J Cancer. 2008 Jul 22;99(2):245-52.
  • Akbay EA,Contreras CM,Perera SA,Sullivan JP,Broaddus RR,Schorge JO,Ashfaq R,Saboorian H,Wong KK,Castrillon DH.Differential roles of telomere attrition in type I and II endometrial carcinogenesis.Am J Pathol. 2008 Aug;173(2):536-44.
  • Zhou X,Bao H,Al-Hashem R,Ji H,Albert M,Wong KK,Sun Y.Magnetic resonance imaging of the response of a mouse model of non-small cell lung cancer to tyrosine kinase inhibitor treatment.Comp Med. 2008 Jun;58(3):276-81.
  • Dutt A,Salvesen HB,Chen TH,Ramos AH,Onofrio RC,Hatton C,Nicoletti R,Winckler W,Grewal R,Hanna M,Wyhs N,Ziaugra L,Richter DJ,Trovik J,Engelsen IB,Stefansson IM,Fennell T,Cibulskis K,Zody MC,Akslen LA,Gabriel S,Wong KK,Sellers WR,Meyerson M,Greulich H.Drug-sensitive FGFR2 mutations in endometrial carcinoma.Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8713-7.
  • Wong KK.Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.Lung Cancer. 2008 Jun;60 Suppl 2:S10-8. Review.
  • Perera SA, Maser RS, Xia H, McNamara K, Protopopov A, Chen L, Hezel AF, Kim CF, Bronson RT, Castrillon DH, Chin L, Bardeesy N, Depinho RA, Wong KK.Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer.Carcinogenesis. 2008 Apr;29(4):747-53.
  • Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ.The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5.
  • Garcia-Barcel MM, Lau DK, Ngan ES, Leon TY, Liu T, So M, Miao X, Lui VC, Wong KK, Ganster RW, Cass DT, Croaker GD, Tam PK.Evaluation of the NK2 Homeobox 1 Gene (NKX2-1) as a Hirschsprung's Disease Locus.Ann Hum Genet. 2008 Mar;72(Pt 2):170-7.
  • Contreras CM, Gurumurthy S, Haynie JM, Shirley LJ, Akbay EA, Wingo SN, Schorge JO, Broaddus RR, Wong KK, Bardeesy N, Castrillon DH.Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas.Cancer Res. 2008 Feb 1;68(3):759-66.
  • Dong Q, Wong KK, Avram AM.Sacral Nerve Root Neurolymphomatosis Diagnosed on FDG-PET/CT and Magnetic Resonance Imaging.Clin Nucl Med. 2008 Jan;33(1):30-1.
  • Deng J, Shimamura T, Perera S, Carlson NE, Cai D, Shapiro GI, Wong KK, Letai A.Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.Cancer Res. 2007 Dec 15;67(24):11867-75.
  • Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jnne PA.PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.Cancer Res. 2007 Dec 15;67(24):11924-32.
  • O'Neil J, Tchinda J, Gutierrez A, Moreau L, Maser RS, Wong KK, Li W, McKenna K, Liu XS, Feng B, Neuberg D, Silverman L, DeAngelo DJ, Kutok JL, Rothstein R, DePinho RA, Chin L, Lee C, Look AT.Alu elements mediate MYB gene tandem duplication in human T-ALL.J Exp Med. 2007 Dec 24;204(13):3059-66.
  • Mok SC,Kwong J,Welch WR,Samimi G,Ozbun L,Bonome T,Birrer MJ,Berkowitz RS,Wong KK.Etiology and pathogenesis of epithelial ovarian cancer.Dis Markers. 2007;23(5-6):367-76. Review.
  • Yuza Y, Glatt KA, Jiang J, Greulich H, Minami Y, Woo MS, Shimamura T, Shapiro G, Lee JC, Ji H, Feng W, Chen TH, Yanagisawa H, Wong KK, Meyerson M.Allele-Dependent Variation in the Relative Cellular Potency of Distinct EGFR Inhibitors.Cancer Biol Ther. 2007 May;6(5):661-7.
  • Tan PK, Wang J, Littler PL, Wong KK, Sweetnam TA, Keefe W, Nash NR, Reding EC, Piu F, Brann MR, Schiffer HH.Monitoring interactions between receptor tyrosine kinases and their downstream effector proteins in living cells using bioluminescence resonance energy transfer.Mol Pharmacol. 2007 Dec;72(6):1440-6.
  • Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro GI, Janne PA, Johnson BE, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless NE, Wong KK.LKB1 modulates lung cancer differentiation and metastasis.Nature. 2007 Aug 16;448(7155):807-10.
  • Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, Perez-Soler R, Riely GJ, Sandler AB, Sequist LV, Socinski MA, Wong KK, Hart CS.Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4583-8.
  • Wong KK.HKI-272 in non small cell lung cancer.Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4593-6. Review.
  • Minami Y, Shimamura T, Shah K, Laframboise T, Glatt KA, Liniker E, Borgman CL, Haringsma HJ, Feng W, Weir BA, Lowell AM, Lee JC, Wolf J, Shapiro GI, Wong KK, Meyerson M, Thomas RK.The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.Oncogene. 2007 Jul 26;26(34):5023-7.
  • Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, Chirieac LR, Padera RF, Lindeman NI, Jnne PA, Thomas RK, Meyerson ML, Eck MJ, Engelman JA, Shapiro GI, Wong KK.Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.Cancer Cell. 2007 Jul;12(1):81-93.
  • Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A, O'Neil J, Gutierrez A, Ivanova E, Perna I, Lin E, Mani V, Jiang S, McNamara K, Zaghlul S, Edkins S, Stevens C, Brennan C, Martin ES, Wiedemeyer R, Kabbarah O, Nogueira C, Histen G, Aster J, Mansour M, Duke V, Foroni L, Fielding AK, Goldstone AH, Rowe JM, Wang YA, Look AT, Stratton MR, Chin L, Futreal PA, DePinho RA.Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers.Nature. 2007 Jun 21;447(7147):966-71.
  • Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, Welch WR, Berkowitz RS, Mok SC.Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas.J Clin Oncol. 2007 Jun 1;25(16):2281-7.
  • Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Thomas RK, Garraway LA, Jnne PA, Johnson BE, Chin L, Wong KK.Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.Cancer Res. 2007 May 15;67(10):4933-9.
  • Wong KK, Maser RS, Sahin E, Bailey ST, Xia H, Ji H, McNamara K, Naylor M, Bronson RT, Ghosh S, Welsh R, Depinho RA.Diminished lifespan and acute stress-induced death in DNA-PKcs-deficient mice with limiting telomeres.Oncogene. 2007 May 3;26(20):2815-21.
  • Christiani DC, Pao W, DeMartini JC, Linnoila RI, Malkinson AM, Onn A, Politi KA, Sharp M, Wong KK, Kim K.BAC consensus conference, November 4-6, 2004: epidemiology, pathogenesis, and preclinical models.J Thorac Oncol. 2006 Nov;1(9 Suppl):S2-7.
  • Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery .Corrigendum: High-throughput oncogene mutation profiling in human cancer.Nat Genet. 2007 Apr;39(4):567.
  • Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA.High-throughput oncogene mutation profiling in human cancer.Nat Genet. 2007 Mar;39(3):347-351.
  • Ngan ES, Sit FY, Lee K, Miao X, Yuan Z, Wang W, Nicholls JM, Wong KK, Garcia-Barcelo M, Lui VC, Tam PK.Implications of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 signaling in human neuroblastoma progression.Clin Cancer Res. 2007 Feb 1;13(3):868-75.
  • Li D, Ji H, Zaghlul S, McNamara K, Liang MC, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Scott AM, Jungbluth AA, Cavenee WK, Old LJ, Demetri GD, Wong KK.Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas.J Clin Invest. 2007 Feb;117(2):346-52.
  • Mok SC, Elias KM, Wong KK, Ho K, Bonome T, Birrer MJ.Biomarker discovery in epithelial ovarian cancer by genomic approaches.Adv Cancer Res.;96:1-22.
  • Wong KK, deLeeuw RJ, Dosanjh NS, Kimm LR, Cheng Z, Horsman DE, MacAulay C, Ng RT, Brown CJ, Eichler EE, Lam WL.A comprehensive analysis of common copy-number variations in the human genome.Am J Hum Genet. 2007 Jan;80(1):91-104.
  • Maser RS, Wong KK, Sahin E, Xia H, Naylor M, Hedberg HM, Artandi SE, DePinho RA.DNA-dependent protein kinase catalytic subunit is not required for dysfunctional telomere fusion and checkpoint response in the telomerase-deficient mouse.Mol Cell Biol. 2007 Mar;27(6):2253-65.
  • Ji H, Sharpless NE, Wong KK.EGFR targeted therapy: view from biological standpoint.Cell Cycle. 2006 Sep;5(18):2072-6. Review.
  • Tonon G, Brennan C, Protopopov A, Maulik G, Feng B, Zhang Y, Khatry DB, You MJ, Aguirre AJ, Martin ES, Yang Z, Ji H, Chin L, Wong KK, Depinho RA.Common and Contrasting Genomic Profiles among the Major Human Lung Cancer Subtypes.Cold Spring Harb Symp Quant Biol. 2005;70:11-24.
  • Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jnne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS.Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.Clin Cancer Res. 2006 Jul 15;12(14):4365s-71s.
  • Dutt A, Wong KK.Mouse models of lung cancer.Clin Cancer Res. 2006 Jul 15;12(14):4396s-402s. Review.
  • Shimamura T, Ji H, Minami Y, Thomas RK, Lowell AM, Shah K, Greulich H, Glatt KA, Meyerson M, Shapiro GI, Wong KK.Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.Cancer Res. 2006 Jul 1;66(13):6487-91.
  • Thomas RK, Nickerson E, Simons JF, Janne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, Gutmann EJ, Dragnev KH, DeBiasi R, Chen TH, Glatt KA, Greulich H, Desany B, Lubeski CK, Brockman W, Alvarez P, Hutchison SK, Leamon JH, Ronan MT, Turenchalk GS, Egholm M, Sellers WR, Rothberg JM, Meyerson M.Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing.Nat Med. 2006 Jul;12(7):852-855.
  • Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Jnne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK.The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.Cancer Cell. 2006 Jun;9(6):485-95.
  • Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung BL, McNamara K, Xia H, Glatt KA, Thomas RK, Sasaki H, Horner JW, Eck M, Mitchell A, Sun Y, Al-Hashem R, Bronson RT, Rabindran SK, Discafani CM, Maher E, Shapiro GI, Meyerson M, Wong KK.Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.Proc Natl Acad Sci U S A. 2006 May 16;103(20):7817-22.
  • Bassres DS, Levantini E, Ji H, Monti S, Elf S, Dayaram T, Fenyus M, Kocher O, Golub T, Wong KK, Halmos B, Tenen DG.Respiratory failure due to differentiation arrest and expansion of alveolar cells following lung-specific loss of the transcription factor C/EBPalpha in mice.Mol Cell Biol. 2006 Feb;26(3):1109-23.
  • Ji H, Houghton AM, Mariani TJ, Perera S, Kim CB, Padera R, Tonon G, McNamara K, Marconcini LA, Hezel A, El-Bardeesy N, Bronson RT, Sugarbaker D, Maser RS, Shapiro SD, Wong KK.K-ras activation generates an inflammatory response in lung tumors.Oncogene. 2006 Mar 30;25(14):2105-12.
  • Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG, Halmos B.An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.Cancer Res. 2005 Aug 15;65(16):7096-101.
  • Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y, Khatry DB, Protopopov A, You MJ, Aguirre AJ, Martin ES, Yang Z, Ji H, Chin L, Depinho RA.High-resolution genomic profiles of human lung cancer.Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9625-30.
  • Wong KK, DePinho RA.Walking the telomere plank into cancer.J Natl Cancer Inst. 2003 Aug 20;95(16):1184-6.
  • DePinho RA, Wong KK.The age of cancer: telomeres, checkpoints, and longevity.J Clin Invest. 2003 Apr;111(7):S9-14.
  • Wong KK, Maser RS, Bachoo RM, Menon J, Carrasco DR, Gu Y, Alt FW, DePinho RA.Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing.Nature. 2003 Feb 6;421(6923):643-8.
  • Wong KK, Chang S, Weiler SR, Ganesan S, Chaudhuri J, Zhu C, Artandi SE, Rudolph KL, Gottlieb GJ, Chin L, Alt FW, DePinho RA.Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation.Nat Genet. 2000 Sep;26(1):85-8.
  • Bardeesy N, Wong KK, DePinho RA, Chin L.Animal models of melanoma: recent advances and future prospects.Adv Cancer Res. 2000;79:123-56.